HIDRADENITIS SUPPURATIVA
Clinical trials for HIDRADENITIS SUPPURATIVA explained in plain language.
Never miss a new study
Get alerted when new HIDRADENITIS SUPPURATIVA trials appear
Sign up with your email to follow new studies for HIDRADENITIS SUPPURATIVA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug tested for painful skin condition after other treatments fail
Disease control OngoingThis study is testing whether an investigational drug called lutikizumab can help adults with moderate-to-severe hidradenitis suppurativa, a painful inflammatory skin condition. The research focuses on people who haven't gotten enough benefit from previous anti-TNF treatments, wi…
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Botox trial for chronic skin disease withdrawn before starting
Disease control TerminatedThis study aimed to test whether Botox injections could help control hidradenitis suppurativa, a painful skin condition that causes recurring abscesses and nodules. The trial planned to enroll people with active underarm lesions to see if Botox could reduce the number and severit…
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE4 • Sponsor: Yale University • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial targets painful skin condition
Disease control OngoingThis study is testing whether anifrolumab, an existing immune-system drug, can help control hidradenitis suppurativa (HS), a chronic inflammatory skin condition. Fifteen adults with moderate-to-severe HS will receive the drug intravenously over 24 weeks, followed by monitoring. R…
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE2 • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial targets painful skin condition that resists antibiotics
Disease control OngoingThis study is testing an investigational drug called tulisokibart for people with moderate to severe hidradenitis suppurativa (HS), a chronic, painful skin condition. The main goal is to see if the drug can reduce the number of painful abscesses and nodules by at least 50% after …
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug trial offers hope for painful skin condition
Disease control OngoingThis study is testing whether an investigational drug called AVTX-009 can reduce painful skin lesions in people with moderate to severe hidradenitis suppurativa (HS). About 250 participants will receive either AVTX-009 or a placebo for 16 weeks to see which is more effective at c…
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE2 • Sponsor: Avalo Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Skin injection study asks: keep going or take a break?
Disease control OngoingThis study aims to find out if people with moderate to severe hidradenitis suppurativa (HS) who improved on a medication called secukinumab should continue treatment or can safely take a break. About 700 participants who already responded to the drug in earlier studies will be ra…
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New Long-Term skin treatment study seeks to control painful condition
Disease control ENROLLING_BY_INVITATIONThis study aims to learn about the long-term safety and effectiveness of an investigational drug called sonelokimab for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. It is open to about 835 people who have already taken part in a previous…
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New drug trial targets painful skin disease after antibiotics fail
Disease control OngoingThis study is testing an investigational drug called eltrekibart for adults with moderate-to-severe hidradenitis suppurativa (HS), a painful chronic skin condition. The main goal is to find the safest and most effective dose and dosing schedule to reduce the number of painful abs…
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Five new weapons in the fight against painful skin disease
Disease control OngoingThis study is testing five different new drugs to see if they can help people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. It involved 248 participants who received either one of the drugs or a placebo for 16 weeks. The main goal was to see if …
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New Drug's Long-Term safety tested for painful skin condition
Disease control OngoingThis study aims to check the long-term safety of the drug bimekizumab in people with moderate to severe hidradenitis suppurativa (HS), a chronic and painful skin condition. It is an extension study for 658 participants who completed a previous bimekizumab trial. The main goal is …
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New cell therapy aims to tame painful skin disease
Disease control OngoingThis early-stage study is testing the safety of SBT777101, a new treatment for hidradenitis suppurativa (HS). The therapy uses a patient's own immune cells, modified to target and calm inflammation in affected skin. Researchers will give single doses to 24 adults with moderate-to…
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE1 • Sponsor: Sonoma Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC
-
New drug trial targets painful skin condition
Disease control OngoingThis study is testing whether an oral drug called brensocatib can reduce painful lumps and abscesses in adults with moderate to severe hidradenitis suppurativa, a chronic inflammatory skin disease. About 214 participants will receive either the drug or a placebo for 16 weeks to s…
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE2 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Feb 27, 2026 15:17 UTC
-
Real-World study follows Patients' pain and odor relief from skin condition treatment
Symptom relief OngoingThis study aims to understand how patients with hidradenitis suppurativa (HS) experience their symptoms after starting a medication called secukinumab. Researchers will follow 192 adults in France for up to two years, asking them to report on pain, oozing, and odor. The goal is t…
Matched conditions: HIDRADENITIS SUPPURATIVA
Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Apr 01, 2026 14:42 UTC
-
Laser zaps away painful skin disease scars
Symptom relief TerminatedThis study aimed to test a special laser treatment to improve the appearance of scars left by hidradenitis suppurativa (HS), a chronic skin condition. It planned to enroll up to 19 adults with HS scars in their underarm area who no longer had active flare-ups. Participants would …
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Mar 25, 2026 14:07 UTC
-
Old dye tested for painful skin condition
Symptom relief TerminatedThis study aimed to see if applying a common antiseptic dye called gentian violet could help people with hidradenitis suppurativa (HS), a painful and chronic skin condition. Researchers planned to survey patients about their pain, skin redness, and drainage before and after a sin…
Matched conditions: HIDRADENITIS SUPPURATIVA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Mar 23, 2026 15:17 UTC
-
Doctors track how they adjust a skin disease drug in real life
Knowledge-focused OngoingThis study aims to understand how doctors in Germany adjust the dose of the approved drug secukinumab for adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. It will observe 424 patients over two years during their routine treatment, tracking w…
Matched conditions: HIDRADENITIS SUPPURATIVA
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC